EDEN PRAIRIE, Minn.,
Dec. 20, 2021 /PRNewswire/ --
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)
("NeuroOne" or the "Company"), a medical technology company focused
on improving surgical care options and outcomes for patients
suffering from neurological disorders, was featured on The
Medical Alley Podcast, in an episode titled "A Conversation
with Dave Rosa, President and CEO,
NeuroOne."
Episode Summary:
"Join us for a conversation with Frank Jaskluke and Dave Rosa, President and CEO of NeuroOne Medical
Technologies Corporation. Dave shares more about the innovation
happening at NeuroOne, which develops thin high-definition film
electrodes that can be used for numerous neurological conditions
including epilepsy."
The episode is also available across podcast platforms including
Medical Alley, Apple, and Spotify:
Medical Alley:
https://medicalalleypodcast.org/episodes/a-conversation-with-dave-rosa-president-and-ceo-neuroone
Apple:
https://podcasts.apple.com/us/podcast/a-conversation-with-dave-rosa-president-and-ceo-neuroone/id1523342401?i=1000544800983
Spotify:https://open.spotify.com/episode/1Q8I0J1jLgGTWKeEvpmQjK?si=Gi1BTJkzRMyTPaEj_DUbvg
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental
stage company committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and
ablation solutions for patients suffering from epilepsy,
Parkinson's disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders
that may improve patient outcomes and reduce procedural costs. For
more information,
visit https://www.n1mtc.com .
Forward Looking Statements
The podcast may include forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Except for statements of historical fact, any information contained
in this presentation may be a forward–looking statement that
reflects the Company's current views about future events and are
subject to known and unknown risks, uncertainties and other factors
that may cause our actual results, levels of activity, performance
or achievements to be materially different from the information
expressed or implied by these forward-looking statements. In some
cases, you can identify forward–looking statements by the words or
phrases "may," "might," "will," "could," "would," "should,"
"expect," "intend," "plan," "objective," "anticipate," "believe,"
"estimate," "predict," "project," "potential," "target," "seek,"
"contemplate," "continue, "focused on," "committed to" and
"ongoing," or the negative of these terms, or other comparable
terminology intended to identify statements about the future.
Although the Company believes that we have a reasonable basis for
each forward-looking statement, we caution you that these
statements are based on a combination of facts and factors
currently known by us and our expectations of the future, about
which we cannot be certain. Our actual future results may be
materially different from what we expect due to factors largely
outside our control, including risks and uncertainties related to
market and other conditions, the impact of general economic,
industry or political conditions in the United States or
internationally and those described under the heading "Risk
Factors" in our filings with the Securities and Exchange
Commission. These forward–looking statements speak only as of the
date of the podcast and the Company undertakes no obligation to
revise or update any forward–looking statements for any reason,
even if new information becomes available in the future.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuroone-featured-on-the-medical-alley-podcast-a-conversation-with-dave-rosa-president-and-ceo-neuroone-301448190.html
SOURCE NeuroOne Medical Technologies Corporation